New tumour antigen PLAC1/CP1, a potentially useful prognostic marker and immunotherapy target for gastric adenocarcinoma.
about
p53 mutation status is a primary determinant of placenta-specific protein 1 expression in serous ovarian cancers.Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.Kataegis Expression Signature in Breast Cancer Is Associated with Late Onset, Better Prognosis, and Higher HER2 Levels.Placenta-specific protein 1 promotes cell proliferation and invasion in non-small cell lung cancer.Expression and clinical significance of placenta-specific 1 in pancreatic ductal adenocarcinoma.
P2860
New tumour antigen PLAC1/CP1, a potentially useful prognostic marker and immunotherapy target for gastric adenocarcinoma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
New tumour antigen PLAC1/CP1, ...... et for gastric adenocarcinoma.
@en
type
label
New tumour antigen PLAC1/CP1, ...... et for gastric adenocarcinoma.
@en
prefLabel
New tumour antigen PLAC1/CP1, ...... et for gastric adenocarcinoma.
@en
P2093
P2860
P1476
New tumour antigen PLAC1/CP1, ...... et for gastric adenocarcinoma.
@en
P2093
Chunfang Zhang
Danhua Shen
Fangfang Liu
Qiujing Song
Xiaoping Kang
P2860
P304
P356
10.1136/JCLINPATH-2015-202978
P407
P577
2015-07-08T00:00:00Z